TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9456256
Drug: Intermittent filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intermittent filgrastim (300 microg daily one to three times per week to a maximum of 600 microg daily)
Study: 2404346
Drug: Propranolol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60 mg 3 times a day)
Study: 713957
Drug: Biarison (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biarison (900 mg to 1500 mg/day)
Study: 31067745
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 tablets (20,000 IU)
Study: 27068367
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (self-administered action observation treatment)
Study: 25449310
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at P6 point before chemotherapy infusion
Study: 25449310
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg intravenously 30 min before chemotherapy infusion
Study: 22952304
Drug: Constraint-induced therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-induced therapy
Study: 19190563
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL carbohydrate drink 2 hours before surgery
Study: 17237664
Drug: Lacosamide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (100 to 400 mg/d or maximum tolerated dose)
Study: 11466696
Drug: Mylotarg (gemtuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mylotarg (gemtuzumab ozogamicin) therapy
Study: 9466172
Drug: Moclobemide (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (450 mg/day, range 300-600 mg/day)
Study: 9466172
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day, range 10-30 mg/day)
Study: 7737072
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus 2 months use of the tape player
Study: 226306
Drug: estradiol vaginal
Normalized name: Estradiol Vaginal
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estradiol vaginal cream
Study: 226306
Drug: conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: conjugated estrogen cream
Study: 24628553
Drug: Pro+CHO (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro+CHO (20 g intrinsically L-[1-(13)C]-phenylalanine-labeled protein with 60 g carbohydrate)
Study: 24628553
Drug: Pro (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro (20 g intrinsically L-[1-(13)C]-phenylalanine-labeled protein without carbohydrate)
Study: 22952178
Drug: Leucine intake
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine intake of >500 mg · kg⁻¹ · d⁻¹
Study: 22952178
Drug: Leucine intake
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine intake of 500 mg · kg⁻¹ · d⁻¹
Study: 22952178
Drug: Leucine intake
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine intake of 750 mg · kg⁻¹ · d⁻¹
Study: 18275575
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg orally 12 hourly for 24 hours
Study: 18275575
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg orally 12 hourly for 24 hours
Study: 15891564
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of therapy (3-6 months)
Study: 12504699
Drug: Intacs microthin
Normalized name: Babesia microti preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intacs microthin prescription inserts
Study: 10800872
Drug: ZDV 100
Normalized name: ZDV
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZDV 100 mg tid + 200 mg nocte (ZDV-A)
Study: 10800872
Drug: ZDV 250
Normalized name: ZDV
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZDV 250 mg bid (ZDV-B)
Study: 8822458
Drug: MTX dissolved
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX dissolved in saline solution (solution group)
Study: 8822458
Drug: MTX suspensions
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX suspensions (suspension group)
Study: 6986940
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of morphine sulphate (3.5 times the pain-relieving dose, mean 36 mg)
Study: 6986940
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine sulphate (pain-relieving dose, mean 110 mg) administered four-hourly for the first 24 hours, six-hourly for the next 24 hours, and then eight and 20 hours later
Study: 6986940
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine sulphate (pain-relieving dose, mean 140 mg) as required
Study: 23800784
Drug: peg-interferon α‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg-interferon α‐2a at 180 μg/week
Study: 21297523
Drug: GH 33
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 33 μg/kg/d
Study: 21297523
Drug: GH 67
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 67 μg/kg/d
Study: 11158001
Drug: PTH infusion
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH infusion (0.55 U/kg.h for 24 h) before GnRH agonist therapy
Study: 11158001
Drug: PTH infusion
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH infusion (0.55 U/kg.h for 24 h) after 6 months of GnRH agonist therapy
Study: 11158001
Drug: PTH infusion
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH infusion (0.55 U/kg.h for 24 h)
Study: 9663722
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg b.d.)
Study: 9663722
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg b.d.)
Study: 3223435
Drug: Ethanol (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (doses ranging from 0 to 1.05 g/kg lean body weight)
Study: 29343448
Drug: 300‐mg ropivacain/600‐300‐300‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300‐mg ropivacain/600‐300‐300‐mg gabapentin (Group A)
Study: 29343448
Drug: 150‐mg ropivacain/600‐300‐300‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150‐mg ropivacain/600‐300‐300‐mg gabapentin (Group B)
Study: 29343448
Drug: 300‐mg ropivacain/300‐100‐100‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300‐mg ropivacain/300‐100‐100‐mg gabapentin (Group C)
Study: 29343448
Drug: 150‐mg ropivacain/300‐100‐100‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150‐mg ropivacain/300‐100‐100‐mg gabapentin (Group D)
Study: 20627268
Drug: computerized cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: computerized cognitive-behavioral therapy (cCBT)
Study: 16964830
Drug: Amdoxovir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amdoxovir (300 mg orally, twice daily)
Study: 14576731
Drug: Sequential MRD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential MRD monitoring post-ASCT
Study: 10990114
Drug: Heparin-bonded central
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded central venous lines (HB CVLs)
Study: 10990114
Drug: Non-heparin-bonded central
Normalized name: SKIN BOND NON-FLAMMABLE CEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-heparin-bonded central venous lines (NHB CVLs)
Study: 1550145
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin 333 mg every 8 hours from randomization to delivery
Study: 3902238
Drug: mianserin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin (30 mg/day for the first week, then doubled for the next three weeks)
Study: 3902238
Drug: maprotiline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: maprotiline (75 mg/day for the first week, then doubled for the next three weeks)
Study: 27165240
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin 30 mg/m2 and paclitaxel 35 mg/m2 for 5‐6 weeks along with radiotherapy
Study: 15912390
Drug: 0.5% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% aqueous and 0.1% hydrogel formulations of timolol
Study: 2550244
Drug: CGS 16617
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 16617 50 mg/day
Study: 2550244
Drug: Single ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses of CGS 16617 (20 to 100 mg)
Study: 28859672
Drug: Laquinimod (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod (0.9 mg to 2.7 mg, escalating doses)
Study: 26338490
Drug: Coconut oil
Normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut oil application (twice-daily)
Study: 23631607
Drug: Nateglinide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (120 mg three times a day)
Study: 23631607
Drug: Nateglinide and
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nateglinide and Acarbose (both treatments)
Study: 20723033
Drug: Edoxaban 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 5 mg
Study: 25653574
Drug: Edoxaban 30
Normalized name: edoxaban 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 30 mg
Study: 20723033
Drug: All Edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: All Edoxaban doses
Study: 19092465
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2%
Study: 19092465
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of timolol maleate 0.5%/dorzolamide 2%
Study: 17017227
Drug: 5% suspension
Normalized name: Top Cat 4.5% Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% suspension concentrate beta‐cypermethrin (double dose 2S at 100 mg AI/m2)
Study: 17017227
Drug: 5% suspension
Normalized name: Top Cat 4.5% Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% suspension concentrate beta‐cypermethrin (standard dose S at 50 mg AI/m2)
Study: 17017227
Drug: 25% cypermethrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% cypermethrin (CF at 100 mg AI/m2)
Study: 17017227
Drug: 10% permethrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% permethrin (DF at 170 mg AI/m2)
Study: 12818447
Drug: Tinidazole (T)
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole (T) 2g single dose + acidic vaginal gel (M) 2g every 3 days for 3 weeks
Study: 6198368
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral and intravenous administration of kanamycin and metronidazole
Study: 30699842
Drug: Nutraceutical combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical combination (S‐adenosyl methionine; Folinic acid; Omega‐3 fatty acids; 5‐HTP; Zinc picolinate)
Study: 19383806
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg dual-release hydrocortisone tablet
Study: 19383806
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg dual-release hydrocortisone tablet after a high-calorie, high-fat meal
Study: 19383806
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dual-release hydrocortisone tablet
Study: 10994544
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDR) 14 mg/m2
Study: 10994544
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDR) 12 mg/m2
Study: 10994544
Drug: Daunorubicin (DNR)
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin (DNR) 30 mg/m2
Study: 6563903
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 0.1 mg/kg in 15 ml of normal saline
Study: 6563903
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine 0.1 mg/kg and normal saline 15 ml epidurally
Study: 6563903
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 15 ml epidurally and normal saline 0.01 ml/kg intramuscularly
Study: 31930890
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy group (tongdu tiaoshen moxibustion + rehabilitation training)
Study: 30123942
Drug: Risankizumab (0.01-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab (0.01-5 mg/kg IV, 0.25-1 mg/kg SC, 18 mg SC, 90 mg SC, 180 mg SC for psoriasis; 200 or 600 mg IV every 4 weeks followed by 180 mg SC every 8 weeks for Crohn's disease)
Study: 27487251
Drug: Digital medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital medicine system (DMS) with wearable sensor
Study: 22435769
Drug: Videoconferencing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videoconferencing therapy
Study: 17145205
Drug: Captopril 50mg
Normalized name: CAPTOPRIL 50MG TAB
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril 50mg tablet
Study: 12522748
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza virus vaccine with or without intranasal live‐attenuated, cold‐adapted influenza vaccine
Study: 8844501
Drug: Daily subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous injections of inhalant allergens at the maximum intradermally tolerated dose (MITD)
Study: 1477693
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with propofol and alfentanil
Study: 24421901
Drug: Tenofovir administered
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir administered 2 doses/week for 6 weeks
Study: 24421901
Drug: Tenofovir administered
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir administered 4 doses/week for 6 weeks
Study: 24421901
Drug: Tenofovir administered
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir administered 7 doses/week for 6 weeks
Study: 16052841
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg twice/day
Study: 10365650
Drug: Clozapine (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (200-400 mg/d) before and after Sodium Valproate (900-1200 mg/d) for 4 weeks (n = 6)
Study: 1911013
Drug: Flumazenil 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 0.01 mg kg‐1
Study: 6117682
Drug: Live influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live influenza vaccine
Study: 6117682
Drug: Inactivated surface‐antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated surface‐antigen influenza vaccine
Study: 28829884
Drug: Oral Prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Prednisolone (20 mg tablets, 2 tablets once daily for 5 days)
Study: 28829884
Drug: Placebo (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched placebo, 2 tablets once daily for 5 days)
Study: 22878231
Drug: tDCS (transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS (transcranial direct current stimulation) with cathodal stimulation, 20 minutes per day, 5 days per week, for 4 weeks, combined with conventional physical therapy
Study: 22878231
Drug: Sham stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham stimulation combined with conventional physical therapy
Study: 18163509
Drug: Infliximab every
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab every 6 weeks (continuous treatment)
Study: 18163509
Drug: Infliximab upon
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab upon symptom recurrence (on-demand treatment)
Study: 18163509
Drug: Infliximab alone
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab alone (on-demand treatment)
Study: 18163509
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) in combination with infliximab (on-demand treatment)
Study: 14501633
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen during the preoperative period
Study: 8625627
Drug: 0.43 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.43 IU recombinant growth hormone/kg body weight/day for 12 days
Study: 1425873
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied methylprednisolone aceponate (MPA) at the highest dose
Study: 31530840
Drug: GB_a (acidic
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB_a (acidic gel base; 0 ppmF-, pH 4.75)
Study: 31530840
Drug: GB_n (neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB_n (neutral gel base; 0 ppmF-, pH 7.0)
Study: 31530840
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no gel, without/with pellicle)
Study: 29753732
Drug: Extended-release nicotinic
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-release nicotinic acid for 8 weeks
Study: 25342100
Drug: Intradermal acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal acupuncture (IDA) performed continuously on the subject's skin, stimulated at home every night.
Study: 23659181
Drug: Dexibuprofen 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexibuprofen 2.5 or 5 mg/kg (DEX 1)
Study: 23659181
Drug: Dexibuprofen 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexibuprofen 3.5 or 7 mg/kg (DEX 2)
Study: 23659181
Drug: Ibuprofen 5
Normalized name: ibuprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 5 or 10 mg/kg (control)
Study: 20033066
Drug: IL-12 plasmid/lipopolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-12 plasmid/lipopolymer complexes (phIL-12/PPC) at doses of 0.6, 3, 12 or 24 mg m(‐2) once every week for 4 weeks
Study: 12753337
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN) administered as 10 MU QD or TIW for 4 weeks, followed by 5 MU QD or TIW for 20 weeks, and then by 3 MU QD or TIW for 24 weeks, in combination with ribavirin (1.0-1.2 g/day)
Study: 7930412
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of valproate dose
Study: 3265156
Drug: Corticosteroids (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (intravenous methylprednisolone or oral prednisone) at a standard dose of 80 mg/day for 5 days or variable doses of 20-120 mg/day for 4-20 days, along with trimethoprim-sulfamethoxazole (TMP-SMX)
Study: 3265156
Drug: Corticosteroids (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (intravenous methylprednisolone or oral prednisone)
Study: 31061156
Drug: LYS228 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYS228 (multiple intravenous doses)
Study: 31061156
Drug: Placebo (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (multiple intravenous doses)
Study: 31061156
Drug: LYS228 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYS228 (single and multiple intravenous doses)
Study: 25932618
Drug: Memantine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine + Constraint-Induced Aphasia Therapy (CIAT)
Study: 21691756
Drug: Antidiabetic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic medication (oral antidiabetics, insulin, or both)
Study: 15265246
Drug: Quetiapine 150-750
Normalized name: quetiapine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 150-750 mg/day
Study: 9402380
Drug: Brompheniramine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brompheniramine (12 mg) administered at 8:00 A.M. and 8:00 P.M. for ≤ 4 days after onset of symptoms
Study: 8425662
Drug: High insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High insulin infusion (3056 +/‐ 236 pM)
Study: 8425662
Drug: Low insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low insulin infusion (486 +/‐ 33 pM)
Study: 30298673
Drug: Combined antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antioxidant treatment (vitamins, antioxidants, and oligoelements) for six months
Study: 27323611
Drug: Tongxinluo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo Capsule (TC)
Study: 24777981
Drug: Flaxseed (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (30 g of milled flaxseed/d for 6 months)
Study: 22456619
Drug: Vitamin D(2),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(2), 2,000 IU daily for 6 weeks (arm A, control)
Study: 22456619
Drug: Vitamin D(3),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3), 2,000 IU daily for 6 weeks (arm B)
Study: 22456619
Drug: Vitamin D(2),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(2), 50,000 IU weekly for 6 weeks (arm C)
Study: 20600512
Drug: 40 mcg
Normalized name: Caverject 40 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mcg HBV vaccine with 250 mcg GM-CSF